Potent and selective xanthine-based inhibitors of phosphodiesterase 5

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 8, 2007, Pages 2376-2379

  Arnold, Nichola J ^a   Arnold, Ruth ^a   Beer, David ^a   Bhalay, Gurdip ^a   Collingwood, Stephen P ^a   Craig, Sarah ^a   Devereux, Nicholas ^a   Dodds, Mark ^a   Dunstan, Andrew R ^a   Fairhurst, Robin A ^a   Farr, David ^a   Fullerton, Joseph D ^a   Glen, Angela ^a   Gomez, Sylvie ^a   Haberthuer, Sandra ^a   Hatto, Julia D I ^a   Howes, Colin ^a   Jones, Darryl ^a   Keller, Thomas H ^a   Leuenberger, Beate ^b   Moser, Heinz E ^a   Muller, Irene ^b   Naef, Reto ^b   Nicklin, Paul A ^a   Sandham, David A ^a   Turner, Katharine L ^a   Tweed, Morris F ^a   Watson, Simon J ^a   Zurini, Mauro ^b   more..

^a Novartis Institutes of Biomedical Research   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Erectile dysfunction; Phosphodiesterase 5; Xanthine

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; XANTHINE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; ERECTILE DYSFUNCTION; NONHUMAN;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BIOLOGICAL AVAILABILITY; CATTLE; DOGS; ENZYME INHIBITORS; HUMANS; IMPOTENCE; INHIBITORY CONCENTRATION 50; MALE; PHARMACOKINETICS; PROTEIN ISOFORMS; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

CANIS FAMILIARIS;

EID: 33947611124     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.019     Document Type: Article

References (22)

1. Stamford A.W. In: Doherty A.M. (Ed). Annual Reports in Medicinal Chemistry (2002), Academic Press, New York 53
2. Doggrell S.A. Exp. Opin. Pharmacother. 6 (2005) 75
3. Terrett N.K., Bell A.S., Brown D., and Ellis P. Bioorg. Med. Chem. Lett. 6 (1996) 1819
4. Eardley I. Br. J. Urol. 81 (1998) 122
5. Osterloh I.H., and Riley A. Br. J. Clin. Pharmacol. 53 (2002) 219
6. Laties A.M., and Zrenner E. Prog. Retin. Eye Res. 21 (2002) 485
7. Beavo J.A., Rogers N.L., Crofford O.B., Hardman J.G., Sutherland E.W., and Newman E.V. Mol. Pharmacol. 6 (1970) 597
8. Sekhar K.R., Grondin P., Francos S.H., and Corbin J.D. Phosphodiesterase Inhibitors (1996), Academic Press, New York 137
9. Beer D., Bhalay G., Dunstan A., Glen A., Haberthuer S., and Moser H. Bioorg. Med. Chem. Lett. 12 (2002) 1973
10. Arnold R., Beer D., Bhalay G., Baettig U., Collingwood S.P., Craig S., Devereux N., Dunstan A., Glen A., Gomez S., Haberthuer S., Howe T., Jelfs S., Moser H., Naef R., Nicklin P., Sandham D., Stringer R., Turner K., Watson S., and Zurini M. Bioorg. Med. Chem. Lett. 12 (2002) 2587
11. 4 requires 423.1907; found 423.1889.
12. Merlos M., Gomez L., Vericat M.L., Bartroli J., Garcia-Rafanell J., and Forn J. Eur. J. Med. Chem. 25 (1990) 653
13. Bobbitt J.M., Winter D.P., and Kiely J.M. J. Org. Chem. 30 (1965) 2459
14. Dyke S.F., Sainsbury M., and Moon B.J. Tetrahedron 24 (1968) 1467
15. Katayama H., Ohkoshi M., and Yasue M. Chem. Pharm. Bull. 28 (1980) 2226
16. Minter D.E., and Re M.A. J. Org. Chem. 53 (1988) 2653
17. Marivet M.C., Bourguignon J.-J., Lugnier C., Mann A., Stoclet J.-C., and Wermuth C.G. J. Med. Chem. 32 (1989) 1450
18. 50 values were generally within 2-fold of each other.
19. Wang Z., Hop C.E.C.A., Leung K.H., and Pang J. J. Mass Spectrom. 35 (2000) 71
20. Ertl P., Rohde B., and Selzer P. J. Med. Chem. 43 (2000) 3714
21. Artursson P., and Bergstroem C.A.S. Methods Princ. Med. Chem. 18 (2003) 341
22. 3 requires 393.1801; found 393.1801.